Real-time Estimate Cboe BZX 10:27:24 2024-04-25 am EDT 5-day change 1st Jan Change
1.305 USD -1.88% Intraday chart for Femasys Inc. 0.00% +34.36%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
HC Wainwright Adjusts Femasys' Price Target to $12 From $10, Reiterates Buy Rating MT
Femasys Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Femasys Inc. Announces Positive Topline Data from Pivotal Trial for Its Fda-Cleared Femaseed®? for the Treatment of Infertility CI
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution CI
Femasys Inc. Appoints Richard Spector as Chief Commercial Officer CI
Femasys Begins Patient Enrollment for Permanent Birth Control Candidate Trial MT
Femasys Inc. Begins Fembloc Pivotal Trial Enrollment At UC Davis Medical Center, A Hub for Innovation and Groundbreaking Research in Health Care for Women CI
Femasys Inc. Begins Fembloc Pivotal Trial Enrollment At University of Utah CI
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine CI
Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer CI
Femasys Inc. Completes Enrollment of Femaseed Pivotal Trial in Support of Commercial Launch CI
Femasys Inc. announced that it has received $6.85 million in funding from PharmaCyte Biotech, Inc. and other investors CI
Femasys Inc. Appoints Joshua Silverman as Director CI
Femasys Inc. announces tranche update CI
Femasys Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (FEMY) FEMASYS Reports Q3 Revenue $86,186 MT
Femasys Inc. announced that it expects to receive $6.85 million in funding from PharmaCyte Biotech, Inc. CI
Femasys Inc. Successfully Completes the Stage 2 European Union (EU) Medical Device Regulation CI
Top Premarket Decliners MT
Top Midday Gainers MT
HC Wainwright Raises Femasys' Price Target to $13 From $5, Keeps Buy Rating MT
Top Midday Decliners MT
Femasys Activates Enrollment in Trial of FemBloc Birth Control Candidate MT
Femasys Inc. Expands FemBloc Pivotal Trial Enrollment Securing First Academic Site to Participate CI
Top Premarket Decliners MT
Chart Femasys Inc.
More charts
Femasys Inc. is a biomedical company. The Company is focused on addressing unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. The Company also developed a technology platform, namely FemEMB for tissue sampling intended to be marketed alongside its other women-specific medical products in the physician’s office setting.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.33 USD
Average target price
9.75 USD
Spread / Average Target
+633.08%
Consensus
  1. Stock Market
  2. Equities
  3. FEMY Stock
  4. News Femasys Inc.
  5. Sector Update: Health Care Stocks Largely Following Broader Markets Lower